- Home
- ARMN vs GERN Comparison
ARMN vs GERN Comparison
Compare ARMN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- GERN
- Stock Information
- Founded
- ARMN 1992
- GERN 1990
- Country
- ARMN Canada
- GERN United States
- Employees
- ARMN N/A
- GERN N/A
- Industry
- ARMN
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- GERN Health Care
- Exchange
- ARMN Nasdaq
- GERN Nasdaq
- Market Cap
- ARMN 769.7M
- GERN 840.7M
- IPO Year
- ARMN N/A
- GERN 1996
- Fundamental
- Price
- ARMN $5.39
- GERN $1.42
- Analyst Decision
- ARMN
- GERN Buy
- Analyst Count
- ARMN 0
- GERN 11
- Target Price
- ARMN N/A
- GERN $5.80
- AVG Volume (30 Days)
- ARMN 1.4M
- GERN 13.7M
- Earning Date
- ARMN 05-13-2025
- GERN 05-07-2025
- Dividend Yield
- ARMN N/A
- GERN N/A
- EPS Growth
- ARMN 77.15
- GERN N/A
- EPS
- ARMN 0.14
- GERN N/A
- Revenue
- ARMN $510,604,000.00
- GERN $76,994,000.00
- Revenue This Year
- ARMN $49.45
- GERN $208.83
- Revenue Next Year
- ARMN N/A
- GERN $57.49
- P/E Ratio
- ARMN $38.06
- GERN N/A
- Revenue Growth
- ARMN 14.06
- GERN 32386.92
- 52 Week Low
- ARMN $3.29
- GERN $1.17
- 52 Week High
- ARMN $5.65
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- ARMN 61.93
- GERN 44.54
- Support Level
- ARMN $5.24
- GERN $1.17
- Resistance Level
- ARMN $5.53
- GERN $1.47
- Average True Range (ATR)
- ARMN 0.28
- GERN 0.12
- MACD
- ARMN 0.01
- GERN 0.04
- Stochastic Oscillator
- ARMN 76.64
- GERN 83.33
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.